CIAS
SRPT icon

CBIZ Investment Advisory Services’s Sarepta Therapeutics SRPT Stock Holding History

CBIZ Investment Advisory Services’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-500
Closed -$8.55K – 783
2025
Q2 		$8.55K Hold
500
– – ﹤0.01% 371
2025
Q1 		$31.9K Sell
500
-87
-15% -$9.16K ﹤0.01% 159
2024
Q4 		$71.4K Buy
587
+364
+163% +$44.6K ﹤0.01% 94
2024
Q3 		$27.9K Buy
223
+136
+156% +$18.8K ﹤0.01% 149
2024
Q2 		$13.7K Sell
87
-41
-32% -$5.27K ﹤0.01% 222
2024
Q1 		$16.6K Buy
+128
New +$15.7K ﹤0.01% 208

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

CBIZ Investment Advisory Services's SRPT Position: Q3 2025 in Review

CBIZ Investment Advisory Services sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 500 shares — an estimated $8.55K sold.

CBIZ Investment Advisory Services first reported a position in SRPT in Q1 2024 and held it in 6 quarters. The position peaked at $71.4K in Q4 2024. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • CBIZ Investment Advisory Services reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • CBIZ Investment Advisory Services sold 500 Sarepta Therapeutics shares in Q3 2025, an estimated $8.55K.
  • CBIZ Investment Advisory Services first reported a position in Sarepta Therapeutics in Q1 2024 and held it in 6 quarters.
  • CBIZ Investment Advisory Services's Sarepta Therapeutics position peaked at $71.4K in Q4 2024.
  • 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on CBIZ Investment Advisory Services's 13F filing for Q3 2025, filed 6 Nov 2025.